Src inhibitors: Genomics to therapeutics

Expert Opinion on Investigational Drugs

Volumn 10, Issue 7, 2001, Pages 1327-1344

  Sawyer, T ^a   Boyce, B ^a   Dalgarno, D ^a   Iuliucci, J ^a  

^a ARIAD PHARMACEUTICALS INC   (United States)

Author keywords

Cancer; Drug discovery; Inflammation mediated bone loss; Osteoporosis; pp60src; Protein tyrosine kinase; SH2; SH3; Src; Src family kinases; Src homology; Src inhibitors; Structure based drug design

Indexed keywords

2 AMINO 7 (3 TERT BUTYLUREIDO) 6 (2,6 DICHLOROPHENYL)PYRIDO[2,3 D]PYRIMIDINE; 2,3 DIHYDRO 2 OXO 3 (4,5,6,7 TETRAHYDRO 1H INDOL 2 YLMETHYLENE) 1H INDOLE 5 SULFONIC ACID DIMETHYLAMIDE; 6 (2,6 DICHLOROPHENYL) 2 (4 FLUORO 3 METHYLANILINO) 8 METHYL 8H PYRIDO[2,3 D]PYRIMIDIN 7 ONE; AP 21773; AP 22408; AP 22526; CGP 76030; CGP 76775; HALISTANOL TRISULFATE; HERBIMYCIN A; INDOLE DERIVATIVE; INDOLINONE; NVP AAK 980; PD 161570; PD 166285; PROTEIN TYROSINE KINASE; PROTEIN TYROSINE KINASE INHIBITOR; PURINE DERIVATIVE; PURVALANOL B; PYRAZOLOPYRIMIDINE DERIVATIVE; PYRIDOPYRIMIDINE DERIVATIVE; PYRIDOPYRIMIDONE DERIVATIVE; PYRIMIDINE DERIVATIVE; PYRIMIDINONE DERIVATIVE; PYRROLOPYRIMIDINE DERIVATIVE; QUINAZOLINE DERIVATIVE; QUINOLINE DERIVATIVE; RPR 108518 A; STAUROSPORINE; SULFATE; UNCLASSIFIED DRUG; UNINDEXED DRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; CANCER; CATALYSIS; CYTOLOGY; DRUG ACTIVITY; DRUG DESIGN; DRUG EFFICACY; DRUG POTENCY; DRUG RESEARCH; DRUG SELECTIVITY; DRUG STRUCTURE; DRUG SYNTHESIS; IN VITRO STUDY; IN VIVO STUDY; MOLECULAR BIOLOGY; NONHUMAN; ONCOGENE SRC; OSTEOPOROSIS; PROTEIN DOMAIN; REVIEW; VALIDATION PROCESS;

ANIMALS; DRUGS, INVESTIGATIONAL; ENZYME INHIBITORS; HUMANS; MICE; MOLECULAR STRUCTURE; SIGNAL TRANSDUCTION; SRC HOMOLOGY DOMAINS; SRC-FAMILY KINASES;

EID: 0034936328     PISSN: 13543784     EISSN: None     Source Type: Journal    
DOI: 10.1517/13543784.10.7.1327     Document Type: Review

References (176)

1. Cellular functions regulated by Src family kinases
2. c-Src, receptor tyrosine kinases, and human cancer
3. Src inhibitors: Drugs for the treatment of osteoporosis, cancer or both?
4. Tyrosine kinase Src inhibitors: Potential therapeutic applications
5. Identification of a transformation-specific antigen induced by avian sarcoma virus
6. Identification of a polypeptide encoded by the avian sarcoma virus src gene
7. Protein kinase activity associated with the avian sarcoma virus src gene product
8. Transforming gene product of Rous sarcoma virus phosphorylates tyrosine
9. Regulation, substrates and functions of Src
10. The emerging role of protein phosphorylation and cell cycle control in tumor progression
11. Tyrosine kinase inhibition: An approach to drug development
12. Protein tyrosine kinase inhibitors in cancer treatment
13. Inhibitors of tyrosine kinase
14. Protein kinase inhibitors: Structural determinants for target specificity
15. Tyrosine kinases in diseases. Overview of kinase inhibitors as therapeutic agents and current drugs in clinical trials
16. Tyrosine kinase inhibitors in cancer treatment
17. Current progress towards the development of tyrosine kinase inhibitors as anticancer agents
18. Protein kinase inhibitors: The tyrosine-specific kinases
19. The structure-based design of ATP-site directed protein kinases
20. Recent advances in protein kinase inhibition: Current molecular scaffolds used for inhibitor synthesis
21. Kinase inhibitors in cancer therapy
22. The role of oncogenic kinases in human cancer
23. Signal transduction drug discovery: Targets, mechanisms, and structure-based design
24. Protein kinase inhibitors: Emerging pharmacophores 1997-2000
25. Modular binding domains in signal transduction
26. Protein modules and signalling networks
27. SH3 domains and drug design: Ligands, structure, and biological function
28. Src homology-2 domains: Structure, mechanisms, and drug discovery
29. The catalytic activity of Src is dispensable for translocation to focal adhesions but controls the turnover of those structures during cell motility
30. EGF receptor signaling stimulates Src kinase phosphorylation of clathrin, influencing clathrin redistribution and EGF uptake
31. Integrin signalling: A new Cas(t) of characters enters the stage
32. Substrate recognition by osteoclast precursors induces c-Src/microtubule association
33. The product of the proto-oncogene c-Src is modified during cellular response to platelet-derived growth factor
34. c-src
35. c-src tyrosine kinase, myristylation, and modulatory domains are required for enhanced mitogenic responsiveness to epidermal growth factor seen in cells overexpressing c-Src
36. Potentiation of epidermal growth factor receptor-mediated oncogenesis by c-Src: Implications for the etiology of multiple human cancers
37. Activation of c-Src by receptor tyrosine kinases in human colon cancer cells with high metastatic potential
38. STAT3 activation by Src induces specific gene regulation and is required for cell transformation
39. c-Src reduces Bcl-XI expression and reverses the transformed phenotype of cells overexpressing EGF and HER-2 receptors
40. Etk, a Btk family tyrosine kinase, mediates cellular transformation by linking Src to STAT3 activation
41. Co-operative effect of c-Src tyrosine kinase and Stat3 in activation of hepatocyte growth factor expression in mammary carcinoma cells
42. STAT proteins as novel targets for cancer therapy. Signal transducer and activator of transcription
43. New roles for Src kinases in control of cell survival and angiogenesis
44. TRANCE, a TNF family member, activates Atk/PKB through a signalling complex involving TRAF6 and c-Src
45. Genetic evidence for a role for Src family kinases in TNF family signaling and cell survival
46. Selective requirement for Src kinases during VEGF-induced angiogenesis and vascular permeability
47. The vesiculo-vacuolar organelle (VVO): A distinct endothelial cell structure that provides a transcellular pathway for macromolecular extravasation
48. Decreased tumorigenicity of a human colon carcinoma cell line by an antisense expression vector specific for c-Src
49. Downregulation of vascular endothelial growth factor in a human colon carcinoma cell line transfected with an antisense expression vector specific for c-Src
50. Activating SRC mutation in a subset of advanced human colon cancers
51. Activation of Src in human breast tumor cell lines: Elevated levels of phosphotyrosine phosphatase activity that preferentially recognizes the Src carboxy terminal negative regulatory tyrosine 530
52. c-Src protein expression is increased in human breast cancer. An immunohistochemical and biochemical analysis
53. c-src in progressive stages of human colorectal cancer
54. Overexpression of c-Src in areas of hyperproliferation in head and neck cancer, premalignant lesions and benign mucosal disorders
55. Overexpression and activation of the tyrosine kinase Src in human pancreatic carcinoma
56. c-Cbl is downstream of c-Src in a signalling pathway necessary for bone resorption
57. Expression of Src family kinases and their putative substrates in the human preosteoclastic cell line FLG 29.1
58. Pyk2 in osteoclasts is an adhesion kinase, localized in the sealing zone, activation by ligation of alpha(v)beta3 integrin and phosphorylated by Src kinase
59. Decreased c-Src expression enhances osteoblast differentiation and bone formation
60. Nongenotropic, sex nonspecific signaling through the estrogen or androgen receptors: Dissociation from transcriptional activity
61. G protein coupled receptor signaling through the Src and Stat3 pathway: Role in proliferation and transformation
62. Regulation of tyrosine kinase cascades by G-protein-coupled receptors
63. Calcium-dependent epidermal growth factor receptor transactivation mediates the angiotensin II-induced mitogen-activated protein kinase activation in vascular smooth muscle cells
64. Epidermal growth factor receptor transactivation by angiotensin II requires reactive oxygen species in vascular smooth muscle cells
65. 2-mediated injury of endothelial cells
66. Angiotensin II mediated signal transduction. Important role of tyrosine kinases
67. Activation of extracellular signal-regulated kinases (ERK1/2) by angiotensin II is dependent on c-Src invascular smooth muscle cells
68. c-Src activation plays a role in endothelin-dependent hypertrophy of the cardiac myocyte
69. Shear stress activates p60src-Ras-MAPK signalling pathways in vascular endothelial cells
70. Src tyrosine kinases and extracellular signal-regulated kinase 1/2 mitogen-activated protein kinases mediate pressure-induced c-Fos expression in cannulated rat mesenteric small arteries
71. Targeted disruption of the c-Src proto-oncogene leads to osteopetrosis in mice
72. Deficiency of the Hck and Src tyrosine kinases results in extreme levels of extramedullary hematopoiesis
73. c-src in association with intracellular membranes
74. c-src expression for osteoclasts to form ruffled borders and resorb bone in mice
75. Osteopetrosis in Src-deficient mice is due to an autonomous defect of osteoclasts
76. Rescue of osteoclast function by transgenic expression of kinase-deficient Src in src-/- mutant mice
77. Src: A model for regulation of intracellular signaling molecules
78. Knockouts of Src-family kinases: Stiff bones, wimpy T cells, and bad memories
79. T cell development is abolished in mice lacking both Lck and Fyn protein tyrosine kinases
80. Combined deficiencies of Src, Fyn, and Yes tyrosine kinases in mutant mice
81. In vitro and in vivo suppression of osteoclast function by adenovirus vector-induced csk gene
82. The COOH-terminal Src kinase Csk is a tumor antigen in human carcinoma
83. Identification of protein-tyrosine phosphatase 1B as the major tyrosine phosphatase activity capable of dephosphorylating and activating c-Src in several human breast cancer cell lines
84. Impaired osteoclast function in Pyk2 knockout mice and cumulative effects in Pyk2/Src double knockout
85. Engineering unnatural nucleotide specificity for Rous sarcoma virus tyrosine kinase to uniquely label is direct substrates
86. Engineering Src family protein kinases with unnatural nucleotide specificity
87. Design of allele-specific inhibitors to probe protein kinase signalling
88. Generation of monospecific nanomolar tyrosine kinase inhibitors via a chemical genomics approach
89. Structural basis for selective inhibition of Src family kinases by PP1
90. Three-dimensional structure of the tyrosine kinase c-Src
91. The 2.35 Å crystal structure of the inactivated form of chicken Src: A dynamic molecule with multiple regulatory interactions
92. Crystal structures of c-Src reveal features of its autoinhibitory mechanism
93. A tail of two src's: Mutatis mutandis
94. Structure-function relationships in Src family and related protein tyrosine kinases
95. Src family protein tyrosine kinases and cellular signal transduction pathways
96. SH2- and SH3-mediated interactions between focal adhesion kinase and Src
97. Coordinate activation of c-Src by SH3-and SH2-binding sites on a novel p130CAS-related protein, Sin
98. Solution structure of the SH3 domain of Src and identification of its ligand-binding site
99. Solution structure and ligand-binding site of the SH3 domain of the p85 α-subunit of phosphatidylinositol 3-kinase
100. Solution structure of the SH3 domain of phospholipase C-γ
101. Solution structure and ligand-binding of the carboxy-terminal SH3 domain of Grb2
102. Proline-rich sequences that bind to Src homology-3 domains with individual specificities
103. Protein structure-based combinatorial chemistry: Discover of non-peptide binding elements to Src SH3 domain
104. Exploiting the basis of proline recognition by SH3 and WW domains: Design of N-substituted inhibitors
105. Design and synthesis of SH3 domain binding ligands: Modifications of the consensus sequence XPPXP
106. A Sos-derived peptidimer blocks Ras signaling pathway by binding both Grb2 SH3 domains and displays antiproliferative activity
107. Peptidomimetic ligands for Src homology-2 domains
108. Recent advances in the design and synthesis of SH2 inhibitors of Src, Grb2, and ZAP-70
109. Peptidomimetic SH2 domain antagonists for targeting signal transduction
110. Progress in the development of inhibitors of SH2 domains
111. Crystal structure of the phosphotyrosine recognition domain SH2 of v-Src complexed with tyrosine-phosphorylated peptides
112. Binding of a high affinity phosphotyrosyl peptide to the Src SH2 domain: Crystal structures of the complexed and peptide-free forms
113. Peptide inhibitors of Src SH3-SH2-phosphoprotein interactions
114. Molecular basis for interaction of the protein tyrosine kinase ZAP-70 with the T-cell receptor
115. Structural basis for specificity of Grb2-SH2 revealed by a novel ligand binding mode
116. Design, synthesis, and cocrystal structure of a nonpeptide Src SH2 domain ligand
117. src SH2 domain
118. The formation of a covalent complex between a dipeptide ligand and the SRC SH2 domain
119. Structure-based design and synthesis of a novel class of Src SH2 inhibitors
120. Structure-based design of novel bicyclic inhibitors for the Src SH2 domain
121. Structure-based design of an osteoclast-selective, nonpeptide Src homology 2 inhibitor with in vivo antiresorptive activity
122. X-ray structure of citrate bound to Src SH2 leads to high-affinity, bone-targeted Src SH2 inhibitor
123. A novel phosphotyrosine mimetic 4′-carboxymethyloxy-3′-phosphophenylalanine (Cpp): Exploitation in the design of nonpeptide inhibitors of pp60src SH2 domain
124. A Src selective binding compound inhibits osteoclast-mediated bone resorption
125. Bone-targeted Src SH2 inhibitors block Src cellular activity and osteoclast mediated resorption
126. Highly potent inhibitors of the Grb2 SH2 domain
127. Selective Grb2 inhibitors as anti-RAS therapy
128. Effect of potent and selective inhibitors of the Grb2 SH2 domain on cell motility
129. Potent dipeptide inhibitors of the pp60c-src SH2 domain
130. From consensus sequence peptide to high affinity ligand, a library scan strategy
131. SH2-directed ligands of the Lck tyrosine kinase
132. Acquisition of high-affinity, SH2-targeted ligands via a spatially focused library
133. Ligands for the tyrosine kinase p56lck SH2 domain: Discovery of potent dipeptide derivatives with moncharged, nonhydrolyzable phosphate replacements
134. Phosphotyrosine-containing dipeptides as high-affinity ligands for the p56lck SH2 domain
135. Carboxymethyl-phenylalanine as a replacement for phosphotyrosine in SH2 domain binding
136. Crystal structure of Hck in complex with Src family-selective tyrosine kinase inhibitor
137. Structural analysis of the lymphocyte-specific Lck in complex with non-selective and Src family-selective kinase inhibitors
138. Structure of C-terminal Src kinase (CSK) in complex with staurosporine
139. Structural mechanism for STI-571 inhibition of Abelson tyrosine kinase
140. Crystal structure of the activated insulin receptor tyrosine kinase in complex with peptide substrate and ATP analog
141. Structures of the tyrosine kinase domain of fibroblast growth factor receptor in complex with inhibitors
142. Crystal structure of an angiogenesis inhibitor bound to the FGF receptor tyrosine kinase
143. Crystal structure of the kinase domain of human vascular endothelial growth factor receptor 2: A key enzyme in angiogenesis
144. NVP-AAK980, a novel 6-phenylaminoalkylamino-purine derivative, potently inhibits the tyrosine kinase Src and bone resorption
145. Exploiting chemical libraries, structure, and genomics in the search for kinase inhibitors
146. Cyclin-dependent kinase inhibition by new C-2 alkynylated purine derivatives and molecular structure of a CDK2-inhibitor complex
147. Crystal structure of human cyclin-dependent kinase 2 in complex with the adenine-derived inhibitor H717
148. Discovery of a novel, potent, and Src family-selective tyrosine kinase inhibitor
149. Src deficiency or blockade of Src activity in mice provides cerebral protection during stroke
150. A novel inhibitor of the tyrosine kinase Src suppresses phosphorylation of its major cellular substrates and reduces bone resorption in vitro and in rodent models in vivo
151. Tyrosine kinase inhibition in bone metabolism
152. Tyrosine kinase Src inhibitor CGP 76030 suppresses rapid bone loss induced by retinoic acid in rats
153. Structure-activity relationships for a novel series of pyridol[2,3-d]pyrimidine tyrosine kinase inhibitors
154. 2-Substituted aminopyrido[2,3-d]pyrimidin-7(8H)-ones. Structure-activity relationships against selected tyrosine kinases and in vitro and in vivo anticancer activity
155. Biochemical and cellular effects of c-Src kinase-selective pyrido[2,3-d]pyrimidine tyrosine kinase inhibitors
156. Inhibitors of Src tyrosine kinase: The preparation and structure-activity relationship of 4-anilino-3-cyanoquinolines and 4-anilinoquinazolines
157. Synthesis and Src kinase inhibitory activity of a series of 4-phenylamino-3-quinolinecarbonitriles
158. The preparation and SAR of 4-(anilino), 4-(phenoxy), and 4-(thiophenoxy)-quinazolines: Inhibitors of p56lck and EGF-R tyrosine kinase activity
159. SU6656, a selective Src family kinase inhibitor used to probe growth factor signaling
160. Potent and selective inhibitors of the Abl-kinase: Phenylaminopyrimidine (PAP) derivatives
161. Use and selectivity of herbimycin A as inhibitor of protein-tyrosine kinases
162. c-src tyrosine kinase inhibitor, inhibits osteoclastic bone resorption in vitro and hypercalcemia in vivo
163. Evidence that c-Src is involved in the process of osteoclastic bone resorption
164. The marine nature product, halistanol trisulfate, inhibits pp60v-src protein tyrosine kinase activity
165. Combinatorial target-guided ligand assembly: Identification of potent subtype-selective c-Src inhibitors
166. c-src protein tyrosine kinase: Conformational and topographical constraints in peptide design
167. The hallmarks of cancer
168. Cancer-Emerging breakthrough drugs
169. Initial sequencing and analysis of the human genome
170. The sequence of the human genome
171. Therapeutic approaches to bone diseases
172. Emerging therapies for osteoporosis
173. Emerging therapies for the prevention or treatment of postmenopausal osteoporosis
174. Statins: New drugs for treating osteoporosis?
175. The parathyroid hormone, its fragments and analogs-potent bone-builders for treating osteoporosis
176. Cancer and bone